Allarity Therapeutics, Inc. (ALLR)

USD 0.97

(-11.81%)

Market Cap (In USD)

4.3 Million

Revenue (In USD)

-

Net Income (In USD)

-11.9 Million

Avg. Volume

446.51 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.9-373.8
PE
-
EPS
-
Beta Value
0.291
ISIN
US0167443029
CUSIP
016744104
CIK
1860657
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Thomas H. Jensen
Employee Count
-
Website
https://www.allarity.com
Ipo Date
2021-12-21
Details
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.